FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4225391061> ?p ?o ?g. }

• W4225391061 abstract "Breast cancer is the most common cancer that affects women globally and is among the leading cause of women's death. Triple-negative breast cancer is more difficult to treat because hormone therapy is not available for this subset of cancer. The well-established therapy against triple-negative breast cancer is mainly based on surgery, chemotherapy, and immunotherapy. Among the drugs used in the therapy are cisplatin and carboplatin. However, they cause severe toxicity to the kidneys and brain and cause nausea. Therefore, it is urgent to propose new chemotherapy techniques that provide new treatment options to patients affected by this disease. Nowadays, peptide drugs are emerging as a class of promising new anticancer agents due to their lytic nature and, apparently, a minor drug resistance compared to other conventional drugs (reviewed in Jafari et al., 2022). We have recently reported the cytotoxic effect of the antimicrobial peptide LyeTx I-b against glioblastoma cells (Abdel-Salam et al., 2019). In this research, we demonstrated the cytotoxic effect of the peptide LyeTx I-b, alone and combined with cisplatin, against triple-negative cell lines (MDA-MD-231). LyeTx-I-b showed a selectivity index 70-fold higher than cisplatin. The peptide:cisplatin combination (P:C) 1:1 presented a synergistic effect on the cell death and a selective index value 16 times greater than the cisplatin alone treatment. Therefore, an equi-effective reduction of cisplatin can be reached in the presence of LyeTx I-b. Cells treated with P:C combinations were arrested in the G2/M cell cycle phase and showed positive staining for acridine orange, which was inhibited by bafilomycin A1, indicating autophagic cell death (ACD) as a probable cell death mechanism. Furthermore, Western blot experiments indicated a decrease in P21 expression and AKT phosphorylation. The decrease in AKT phosphorylation is indicative of ACD. However, other studies are still necessary to better elucidate the pathways involved in the cell death mechanism induced by the peptide and the drug combinations. These findings confirmed that the peptide LyeTx I-b seems to be a good candidate for combined chemotherapy to treat breast cancer. In addition, in vivo studies are essential to validate the use of LyeTx I-b as a therapeutic drug candidate, alone and/or combined with cisplatin." @default.
• W4225391061 created "2022-05-05" @default.
• W4225391061 creator A5012476473 @default.
• W4225391061 creator A5023379403 @default.
• W4225391061 creator A5049926824 @default.
• W4225391061 creator A5059629950 @default.
• W4225391061 creator A5064534549 @default.
• W4225391061 creator A5084651427 @default.
• W4225391061 creator A5087394781 @default.
• W4225391061 date "2022-05-04" @default.
• W4225391061 modified "2023-10-12" @default.
• W4225391061 title "LyeTxI-b, a Synthetic Peptide Derived From a Spider Venom, Is Highly Active in Triple-Negative Breast Cancer Cells and Acts Synergistically With Cisplatin" @default.
• W4225391061 cites W1504229889 @default.
• W4225391061 cites W1578932543 @default.
• W4225391061 cites W1896032914 @default.
• W4225391061 cites W1969337727 @default.
• W4225391061 cites W1974693247 @default.
• W4225391061 cites W1975200363 @default.
• W4225391061 cites W1976881265 @default.
• W4225391061 cites W1979129905 @default.
• W4225391061 cites W1981631184 @default.
• W4225391061 cites W1987604182 @default.
• W4225391061 cites W1995224853 @default.
• W4225391061 cites W2016318035 @default.
• W4225391061 cites W2032368145 @default.
• W4225391061 cites W2036646583 @default.
• W4225391061 cites W2048722243 @default.
• W4225391061 cites W2087233451 @default.
• W4225391061 cites W2097120982 @default.
• W4225391061 cites W2103562758 @default.
• W4225391061 cites W2112347626 @default.
• W4225391061 cites W2114918609 @default.
• W4225391061 cites W2142486051 @default.
• W4225391061 cites W2146133266 @default.
• W4225391061 cites W2153974668 @default.
• W4225391061 cites W2156797519 @default.
• W4225391061 cites W2162262059 @default.
• W4225391061 cites W2164154441 @default.
• W4225391061 cites W2169183724 @default.
• W4225391061 cites W2233986363 @default.
• W4225391061 cites W2311002816 @default.
• W4225391061 cites W2341763698 @default.
• W4225391061 cites W2407210580 @default.
• W4225391061 cites W2469702515 @default.
• W4225391061 cites W2501520935 @default.
• W4225391061 cites W2517683463 @default.
• W4225391061 cites W2525212277 @default.
• W4225391061 cites W2537893090 @default.
• W4225391061 cites W2551865970 @default.
• W4225391061 cites W2587142564 @default.
• W4225391061 cites W2600452401 @default.
• W4225391061 cites W2602955853 @default.
• W4225391061 cites W2604619953 @default.
• W4225391061 cites W2620036274 @default.
• W4225391061 cites W2752326209 @default.
• W4225391061 cites W2765386661 @default.
• W4225391061 cites W2774112395 @default.
• W4225391061 cites W2796387102 @default.
• W4225391061 cites W2883418948 @default.
• W4225391061 cites W2884653672 @default.
• W4225391061 cites W2889646458 @default.
• W4225391061 cites W2894883173 @default.
• W4225391061 cites W2897926526 @default.
• W4225391061 cites W2901090149 @default.
• W4225391061 cites W2905399276 @default.
• W4225391061 cites W2949451864 @default.
• W4225391061 cites W2952418011 @default.
• W4225391061 cites W2981108749 @default.
• W4225391061 cites W3015178699 @default.
• W4225391061 cites W3168476650 @default.
• W4225391061 cites W3201235440 @default.
• W4225391061 cites W4212871239 @default.
• W4225391061 cites W4239622015 @default.
• W4225391061 cites W588205466 @default.
• W4225391061 cites W80971072 @default.
• W4225391061 doi "https://doi.org/10.3389/fmolb.2022.876833" @default.
• W4225391061 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35601827" @default.
• W4225391061 hasPublicationYear "2022" @default.
• W4225391061 type Work @default.
• W4225391061 citedByCount "2" @default.
• W4225391061 countsByYear W42253910612023 @default.
• W4225391061 crossrefType "journal-article" @default.
• W4225391061 hasAuthorship W4225391061A5012476473 @default.
• W4225391061 hasAuthorship W4225391061A5023379403 @default.
• W4225391061 hasAuthorship W4225391061A5049926824 @default.
• W4225391061 hasAuthorship W4225391061A5059629950 @default.
• W4225391061 hasAuthorship W4225391061A5064534549 @default.
• W4225391061 hasAuthorship W4225391061A5084651427 @default.
• W4225391061 hasAuthorship W4225391061A5087394781 @default.
• W4225391061 hasBestOaLocation W42253910611 @default.
• W4225391061 hasConcept C121608353 @default.
• W4225391061 hasConcept C126322002 @default.
• W4225391061 hasConcept C143998085 @default.
• W4225391061 hasConcept C154317977 @default.
• W4225391061 hasConcept C185592680 @default.
• W4225391061 hasConcept C202751555 @default.
• W4225391061 hasConcept C203014093 @default.
• W4225391061 hasConcept C2776694085 @default.
• W4225391061 hasConcept C2778239845 @default.
• W4225391061 hasConcept C2780110267 @default.

• next